Spots Global Cancer Trial Database for TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Official Title: Phase 1 Dose Escalating Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma
Study ID: NCT00243763
Conditions
Interventions
Study Description
Brief Summary: The primary objective of this study is to determine the maximum tolerated dose (MTD), dose limiting toxicity (DLT), and safety profile of CHIR-258 when administered to subjects with refractory or relapsed multiple myeloma (MM).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Mayo Clinic - Arizona, Scottsdale, Arizona, United States
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States
Emory University, Atlanta, Georgia, United States
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Mayo Clinic - Minnesota, Rochester, Minnesota, United States
Contact Details
Name: Novartis
Affiliation: Novartis
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
